$吉利德科学(GILD)$ 4月21日瑞德西韦来自休斯敦医院临床的好消息-Katherine K. Perez表示早期结果有希望，药物很耐受，不少接受瑞德西韦治疗的病人康复出院了，用瑞德西韦治疗的病人很可能可以免于插管Katherine K. Perez, PharmD, an infectious diseases pharmacist at Houston Methodist Hospital, another trial site, noted that “early results are promising” there, too. In a press release from the hospital, she explained that “courses have been well tolerated, and a number of COVID-19 patients who have undergone treatment with remdesivir are showing signs of recovery and have been released from the hospital to go home.” Acknowledging that it is too early to tell, Dr. Perez noted that there are “indications that treatment with remdesivir can possibly stave off” intubation.

Dr. Kevin Grimes表示：及时用药非常关键，如果用药早，我们希望瑞德西韦可以阻止病毒复制，这样病人可以避免病情恶化到插管上呼吸机The patients with moderate illness receive either five or 10 days of remdesivir treatment, while those with severe illness receive 10 days of treatment with the drug.Quick treatment is critical, said Dr. Kevin Grimes, an infectious diseases physician and co-leader of the trials."If given early enough, we're hoping that remdesivir interferes with the virus and blocks its ability to replicate in patients' cells," Grimes said in a Houston Methodist news release. "The goal is that it staves off the deadly inflammatory cascade that leads to respiratory failure and the need to be intubated and put on a ventilator." 原文链接：网页链接